1 |
Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)[J]. JAMA, 2003, 289(23): 3095-3105.
|
2 |
Labonté B, Engmann O, Purushothaman I, et al. Sex-specific transcriptional signatures in human depression[J]. Nat Med, 2017, 23(9): 1102-1111.
|
3 |
Mandelli L, Serretti A. Gene environment interaction studies in depression and suicidal behavior: an update[J]. Neurosci Biobehav Rev, 2013, 37(10Pt 1): 2375-2397.
|
4 |
Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010[J]. PLoS Med, 2013, 10(11): e1001547.
|
5 |
Hing B, Sathyaputri L, Potash JB. A comprehensive review of genetic and epigenetic mechanisms that regulate BDNF expression and function with relevance to major depressive disorder[J]. Am J Med Genet B Neuropsychiatr Genet, 2018, 177(2): 143-167.
|
6 |
Hoffmann A, Sportelli V, Ziller M, et al. Epigenomics of major depressive disorders and schizophrenia: early life decides[J]. Int J Mol Sci, 2017, 18(8): E1711.
|
7 |
de Sousa RT, Loch AA, Carvalho AF, et al. Genetic studies on the tripartite glutamate synapse in the pathophysiology and therapeutics of mood disorders[J]. Neuropsychopharmacology, 2017, 42(4): 787-800.
|
8 |
Klengel T, Binder EB. Gene-environment interactions in major depressive disorder[J]. Can J Psychiatry, 2013, 58(2): 76-83.
|
9 |
Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis[J]. Am J Psychiatry, 2000, 157(10): 1552-1562.
|
10 |
Nishino J, Ochi H, Kochi Y, et al. Sample size for successful genome-wide association study of major depressive disorder[J]. Front Genet, 2018, 9: 227.
|
11 |
Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A mega-analysis of genome-wide association studies for major depressive disorder[J]. Mol Psychiatry, 2013, 18(4): 497-511.
|
12 |
Hyde CL, Nagle MW, Tian C, et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent[J]. Nat Genet, 2016, 48(9): 1031-1036.
|
13 |
Menke A, Arloth J, Pütz B, et al. Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients[J]. Neuropsychopharmacology, 2012, 37(6): 1455-1464.
|
14 |
Guilloux JP, Bassi S, Ding Y, et al. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression[J]. Neuropsychopharmacology, 2015, 40(3): 701-710.
|
15 |
Jansen R, Penninx BW, Madar V, et al. Gene expression in major depressive disorder[J]. Mol Psychiatry, 2016, 21(3): 339-347.
|
16 |
Mostafavi S, Battle A, Zhu X, et al. Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing[J]. Mol Psychiatry, 2014, 19(12): 1267-1274.
|
17 |
Lin E, Tsai SJ. Genome-wide microarray analysis of gene expression profiling in major depression and antidepressant therapy[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2016, 64: 334-340.
|
18 |
Yi ZH, Li ZZ, Yu SY, et al. Blood-based gene expression profiles models for classification of subsyndromal symptomatic depression and major depressive disorder[J]. PLoS One, 2012, 7(2): e31283.
|
19 |
Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments[J]. Stat Appl Genet Mol Biol, 2004, 3: Article3.
|
20 |
Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis[J]. BMC Bioinformatics, 2008, 9: 559.
|
21 |
Smith RS. The macrophage theory of depression[J]. Med Hypotheses, 1991, 35(4): 298-306.
|
22 |
Maes M. Evidence for an immune response in major depression: a review and hypothesis[J]. Prog Neuropsychopharmacol Biol Psychiatry, 1995, 19(1): 11-38.
|
23 |
Dantzer R, O′Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain[J]. Nat Rev Neurosci, 2008, 9(1): 46-56.
|
24 |
Felger JC. Imaging the role of inflammation in mood and anxiety-related disorders[J]. Curr Neuropharmacol, 2018, 16(5): 533-558.
|
25 |
Patel A. Review: the role of inflammation in depression[J]. Psychiatr Danub, 2013, 25(): S216-S223.
|
26 |
Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder[J]. J Affect Disord, 2014, 169: 15-20.
|
27 |
Noto C, Rizzo LB, Mansur RB, et al. Targeting the inflammatory pathway as a therapeutic tool for major depression[J]. Neuroimmunomodulation, 2014, 21(2/3): 131-139.
|
28 |
de Melo LGP, Nunes SOV, Anderson G, et al. Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2017, 78: 34-50.
|
29 |
Wang QZ, Roy B, Turecki G, et al. Role of complex epigenetic switching in tumor necrosis factor-α upregulation in the prefrontal cortex of suicide subjects[J]. Am J Psychiatry, 2018, 175(3): 262-274.
|
30 |
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target[J]. Nat Rev Immunol, 2016, 16(1): 22-34.
|
31 |
Kappelmann N, Lewis G, Dantzer R, et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions[J]. Mol Psychiatry, 2018, 23(2): 335-343.
|
32 |
Du W, Bautista JF, Yang HH, et al. Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder[J]. Nat Genet, 2005, 37(7): 733-738.
|
33 |
Baudewijns L, Ronsse E, Verstraete V, et al. Problem behaviours and major depressive disorder in adults with intellectual disability and autism[J]. Psychiatry Res, 2018, 270: 769-774.
|